Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026827 (
hypotonia
)
5,860
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Three unrelated adult patients with mild hyperglycinemia, infantile
hypotonia
, mental retardation, behavioral hyperirritability, and aggressive outbursts were screened for
glycine decarboxylase
(
GLDC
) mutations; two novel missense mutations (A389V and R739H) were found. Both mutations had a 6 to 8% of normal
GLDC
activities when expressed in COS7 cells.
...
PMID:Glycine decarboxylase mutations: a distinctive phenotype of nonketotic hyperglycinemia in adults. 1582 56
Glycine encephalopathy (GE) (non-ketotic hyperglycinemia) is an autosomal recessive neurometabolic disease caused by defective activity of the glycine cleavage system. Clinically, patients present usually in the neonatal period with
hypotonia
, encephalopathy, hiccups and breath arrests with or without overt seizures. GE is considered rare, but its incidence is relatively high in several geographical areas around the world. We report a novel mutation causing GE in six extended Arab families, all from a small suburban village (population 5,000). A methionine to threonine change in the initiation codon of the
glycine decarboxylase
gene led to markedly reduced
glycine decarboxylase
mRNA levels and abolished glycine cleavage system activity.
...
PMID:A single nucleotide substitution that abolishes the initiator methionine codon of the GLDC gene is prevalent among patients with glycine encephalopathy in Jerusalem. 1586 13
Nonketotic hyperglycinemia (OMIM #605899), also known as glycine encephalopathy, is an autosomal recessive disorder of glycine metabolism caused by a defect in the glycine cleavage system. A term neonate developed progressive lethargy, muscular
hypotonia
, and respiratory insufficiency on day 2 after birth, but no overt clinical seizures. Amplitude-integrated electroencephalography indicated a continuous burst-suppression pattern. The diagnosis of nonketotic hyperglycinemia was made biochemically and was confirmed by genetic studies, which revealed two missense mutations (one not previously described) within the
glycine decarboxylase
gene, GLDC. Nonketotic hyperglycinemia should be incorporated into the differential diagnosis of neonatal
hypotonia
, to avoid an erroneous diagnosis of sepsis or hypoxic ischemic injury. Amplitude-integrated electroencephalography may be helpful in the initial assessment of severely sick and hypotonic neonates without overt clinical seizures, and may direct further diagnostic evaluation.
...
PMID:A novel missense mutation in a neonate with nonketotic hyperglycinemia. 2093 83
Nonketotic hyperglycinemia (NKH), or glycine encephalopathy, is an autosomal recessive disorder caused by a defect in the glycine cleavage enzyme system. In neonatal-onset NKH, patients manifest lethargy,
hypotonia
, apnea, and intractable epileptic seizures that are not specific to this disease. We experienced a 6-year-old girl with spastic quadriplegia, intractable epilepsy, and mental retardation, all initially regarded as sequelae of neonatal meningitis. The seizure frequency was transiently increased when valproate was started. Head MRI revealed progressive brain atrophy and white matter loss with high intensity signals on T2-weighted and diffusion-weighted images, which prompted us to conduct further metabolic workups. High glycine levels led us to suspect NKH, and we confirmed this diagnosis by the non-invasive, (13)C-glycine breath test. DNA sequencing revealed novel Leu885Pro/Trp897Cys mutations in the
glycine decarboxylase
gene that were transmitted from both parents. Sodium benzoate and dextromethorphan dramatically decreased her hypertonicity. Our case shows that paradoxical increases in seizure frequency following valproate can be a clue for a diagnosis of NKH, and that a correct diagnosis of NKH can greatly alter the quality of life in such patients.
...
PMID:Paradoxical increase in seizure frequency with valproate in nonketotic hyperglycinemia. 2131 84
Nonketotic hyperglycinemia, also known as glycine encephalopathy, is an autosomal recessive disorder of an inborn error of the glycine metabolism, caused by deficiency in the mitochondrial glycine cleavage enzyme. The majority of cases are caused by mutations in
P-protein
, one of the four components of the glycine cleavage enzyme,
glycine decarboxylase
. We describe a male neonate with
hypotonia
, hiccups, and persistent apnea, but without seizures. The patient's glycine level in cerebrospinal fluid and plasma was 328.3 nmol/mL (reference value, 2.2-14.2 nmol/mL) and 1439 nmol/mL (reference value, 232-740 nmol/mL), respectively. The cerebrospinal fluid/plasma ratio of 0.228 represented an increase (normal range, <0.04). Two novel heterozygous missense mutations (c.1130C>T (p.A377V) and c.2081_2088del (p.A694DfsX11) in exons 8 and 18) in the
glycine decarboxylase
gene confirmed the diagnosis of nonketotic hyperglycinemia.
...
PMID:Two novel missense mutations observed in nonketotic hyperglycinemia. 2263 39
Glycine encephalopathy (GCE) or nonketotic hyperglycinemia is an inborn error of glycine metabolism, inherited in an autosomal recessive manner due to a defect in any one of the four enzymes aminomethyltransferase (AMT),
glycine decarboxylase
(
GLDC
), glycine cleavage system protein-H (GCSH) and dehydrolipoamide dehydrogenase in the glycine cleavage system. This defect leads to glycine accumulation in body tissues, including the brain, and causes various neurological symptoms such as encephalopathy,
hypotonia
, apnea, intractable seizures and possible death. We screened 14 patients from 13 families with clinical and biochemical features suggestive of GCE for mutation in AMT,
GLDC
and GCSH genes by direct sequencing and genomic rearrangement of
GLDC
gene using a multiplex ligation-dependant probe amplification. We identified mutations in all 14 patients. Seven patients (50%) have biallelic mutations in
GLDC
gene, six patients (43%) have biallelic mutations in AMT gene and one patient (7%) has mutation identified in only one allele in
GLDC
gene. Majority of the mutations in
GLDC
and AMT were missense mutations and family specific. Interestingly, two mutations p.Arg265His in AMT gene and p.His651Arg in
GLDC
gene occurred in the Penan sub-population. No mutation was found in GCSH gene. We concluded that mutations in both
GLDC
and AMT genes are the main cause of GCE in Malaysian population.
...
PMID:Mutation analysis of glycine decarboxylase, aminomethyltransferase and glycine cleavage system protein-H genes in 13 unrelated families with glycine encephalopathy. 2523 68
FOXP1 (forkhead box
protein P1
) is a transcription factor involved in the development of several tissues, including the brain. An emerging phenotype of patients with protein-disrupting FOXP1 variants includes global developmental delay, intellectual disability and mild to severe speech/language deficits. We report on a female child with a history of severe
hypotonia
, autism spectrum disorder and mild intellectual disability with severe speech/language impairment. Clinical exome sequencing identified a heterozygous de novo FOXP1 variant c.1267_1268delGT (p.V423Hfs*37). Functional analyses using cellular models show that the variant disrupts multiple aspects of FOXP1 activity, including subcellular localization and transcriptional repression properties. Our findings highlight the importance of performing functional characterization to help uncover the biological significance of variants identified by genomics approaches, thereby providing insight into pathways underlying complex neurodevelopmental disorders. Moreover, our data support the hypothesis that de novo variants represent significant causal factors in severe sporadic disorders and extend the phenotype seen in individuals with FOXP1 haploinsufficiency.
...
PMID:A de novo FOXP1 variant in a patient with autism, intellectual disability and severe speech and language impairment. 2585 99
Non-ketotic hyperglycinemia (NKH) is a rare inborn error of metabolism and is caused by a glycine cleavage system deficiency. Eighty-five percent of patients present with the neonatal type of NKH, the infants initially develop lethargy, seizures, and episodes of apnea, and most often death. Between 60-90% of cases are caused by mutations in the
glycine decarboxylase
(
GLDC
). We believed that more mutation reports especially for rare disease as NKH help to evaluate the genotype-phenotype relationship in patients with
GLDC
. In this study, we describe a case of a neonate admitted to intensive care unit with
hypotonia
, respiratory failure, lethargy, poor feeding. Due to the history of 2 non-ketotic hyperglycinemia diagnosed male siblings, molecular prenatal diagnosis in patient was performed and a novel c.2963G>A (Arg998Gln) homozygous mutation within the
GLDC
gene has been detected. We aimed to contribute to mutation knowledge pool of
GLDC
gene with a novel mutation.
...
PMID:A novel mutation in the glycine decarboxylase gene in patient with non-ketotic hyperglycinemia. 2841 85
Nonketotic hyperglycinemia (NKH) is an autosomal recessive hereditary disease caused by a defect in the glycine cleavage system and is classified into typical and atypical NKH. Atypical NKH has complex manifestations and is difficult to diagnose in clinical practice. This article reports a family of NKH. The parents had normal phenotypes, and the older brother and the younger sister developed this disease in the neonatal period. The older brother manifested as intractable epilepsy, severe spastic diplegia, intellectual disability, an increased level of glycine in blood and cerebrospinal fluid, an increased glycine/creatinine ratio in urine, and an increased ratio of glycine concentration in cerebrospinal fluid and blood. The younger sister manifested as delayed language development, ataxia, chorea, mental and behavior disorders induced by pyrexia,
hypotonia
, an increased level of glycine in cerebrospinal fluid, and an increased ratio of glycine concentration in cerebrospinal fluid and blood. High-throughput sequencing found a maternal missense mutation, c.3006C>G (p.C1002W), and a paternal nonsense mutation, c.1256C>G (p.S419X), in the GLDC gene in both patients. These two mutations were thought to be pathogenic mutations by a biological software. H293T cells transfected with these two mutants of the GLDC gene had a down-regulated activity of
glycine decarboxylase
. NKH has various phenotypes, and high-throughput sequencing helps to make a confirmed diagnosis. Atypical NKH is associated with the downregulated activity of
glycine decarboxylase
caused by gene mutations.
...
PMID:[Clinical and genetic analyses of a family with atypical nonketotic hyperglycinemia caused by compound heterozygous mutations in the GLDC gene]. 2904 6